ClinicalTrials.gg
CompletedNCT03873493Updated Dec 19, 2022Results posted

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

A Phase 2 interventional study of Venetoclax and Ibrutinib in Leukemia, T-cell Prolymphocytic Leukemia (T-PLL) and Cancer, sponsored by AbbVie. Completed at 15 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-19.

Primary conditionLeukemia, Prolymphocytic, T-CellRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Prolymphocytic, T-Cell
Why
  1. The study's listed conditions name Leukemia, Prolymphocytic, T-Cell, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Leukemia, Prolymphocytic, T-Cell · United States.

Enrollment
19th of 23
14 · median 30
Started
2020
with 2 others
Phase 2
7 of 24
2 open now
Registered
11th of 24
by date
Lead sponsor
1 of 24
AbbVie

Among the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, this one is the 19th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 11th registered.

Leukemia, Prolymphocytic, T-Cell

30 studies on the registry are indexed under Leukemia, Prolymphocytic, T-Cell; 8 are open to participants now.

Browse Leukemia, Prolymphocytic, T-Cell studies →

Open to participants now

6 of the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Leukemia, Prolymphocytic, T-Cell studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of the combination of venetoclax plus ibrutinib for treating adults with T-cell prolymphocytic leukemia (T-PLL).

Read the detailed description

This study is planned as an adaptive 2-stage design as follows:

Stage 1: Enroll 14 participants with relapsed or refractory (R/R) T-PLL and move to Stage 2 if 4 or more participants meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment.

Stage 2: Enroll up to an additional 23 participants.

The study was stopped after Stage 1. Stage 2 was not conducted.

03

Conditions studied

  • Leukemia
  • T-cell Prolymphocytic Leukemia (T-PLL)
  • Cancer

Browse trials for

Keywords

  • T-cell Prolymphocytic Leukemia (T-PLL)
  • Cancer
  • Venetoclax
  • Venclexta
  • Venclyxto
  • Ibrutinib
  • Imbruvica
  • Relapsed or Refractory T-lymphoid malignancy
04

In context

Leukemia, Prolymphocytic, T-Cell Reclassified

30 studies on the registry are indexed under Leukemia, Prolymphocytic, T-Cell; 8 are open to participants now.

This study's enrollment of 14 is below the median of 30 across 28 interventional studies indexed under Leukemia, Prolymphocytic, T-Cell.

Browse Leukemia, Prolymphocytic, T-Cell studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Leukemia, Prolymphocytic, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate liver, kidney and hematology function per laboratory values as described in the protocol.
  • Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.
  • (ECOG) performance status less than or equal to 2.
  • Received prior alemtuzumab (unless unsuitable or unavailable).
  • Has no other than T-PLL that:

    • currently require systemic therapies;
    • were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or
    • developed signs of progression after curative treatment.

Exclusion criteria

Exclusion Criteria:

  • History of or current decompensated cirrhosis including class B or C, ascites, hepatic encephalopathy, or variceal bleeding.
  • Has human T-cell lymphotropic virus, type 1.
  • Prior stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy.
  • Has an uncontrolled or active infection including severe acute respiratory syndrome- coronavirus-2 (SARS-COV-2).
  • Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.
  • Received a prohibited therapy within the specified time frame as described in the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Venetoclax + Ibrutinib

    Participants received 400 mg venetoclax orally once a day after a 5-day ramp-up and 420 mg ibrutinib orally once a day for up to 2 years or until progressive disease, intolerability, or they became eligible for stem cell transplantation after achieving complete remission.

    Drug: Venetoclax · Drug: Ibrutinib

Interventions

  • Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.

    Also known as: ABT-199, GDC-0199, Venclexta®, Venclyxto®

  • Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.

    Also known as: Imbruvica®

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial remission (PR) as their best response per investigator assessment based on the T-PLL consensus criteria 2019. CR: All of the following response criteria must be met: Group A: * all lymph nodes \< 1 cm; * spleen \< 13 cm; * no constitutional symptoms; * circulating lymphocyte count \< 4 × 10\^9/L; * bone marrow T-PLL cells \< 5% of mononuclear cells; * no other specific site involvement Group B: * platelets ≥ 100 × 10\^9 /L; * hemoglobin ≥ 11.0 g/dL; * neutrophils ≥ 1.5 × 10\^9 /L. CRi: All of the CR response criteria in Group A met; at least 1 parameter in Group B not achieved, unrelated to T-PLL, but related to drug toxicity. PR: At least 2 of the parameters in Group A and 1 parameter in Group B need to improve if previously abnormal. If only 1 parameter of both Groups A and B is abnormal prior to therapy, only 1 parameter needs to improve.

    Time frame: Clinical response was assessed at Weeks 4, 8, 12, 16, and 24 for ORR assessment

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from the date of first dose of any study drug to the date of earliest disease progression or death. PFS was calculated using Kaplan-Meier methods. Response was assessed by the investigator based on the T-PLL consensus criteria 2019. Progressive disease (PD) is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in sum of long-axis diameters of up to 3 target lesions (SLD) from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  2. Duration of Response (DOR)

    Duration of response is defined for participants who achieved a best overall response of CR, CRi, or PR as the time from the date of first response (CR, CRi, or PR) to the earliest date of disease progression or death. DOR was calculated using Kaplan-Meier methods. Response was assessed by the investigator based on the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  3. Time to Progression (TTP)

    Time to progression is defined as the time from the date of the participant's first dose of any study drug to the date of earliest disease progression. TTP was calculated using Kaplan-Meier methods. Clinical response (laboratory and physical examination assessments) was assessed by the investigator according to the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  4. Event-free Survival (EFS)

    Event-free survival is defined as time from participant's first dose of any study drug to the date of earliest disease progression, death, or start of a new anti-T-PLL therapy. EFS was calculated using Kaplan-Meier methods. Clinical response (laboratory and physical examination assessments) was assessed by the investigator according to the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  5. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieved CR, CRi, PR, or stable disease (SD) as best overall response per investigator assessment based on the T-PLL consensus criteria 2019. Stable disease is defined as meeting all of the following criteria for at least 3 months: * lymph nodes change of -29% to +20% in SLD; * spleen change of -49% to +49% beyond normal from baseline; * circulating lymphocyte count \> 30 × 10\^9 /L or change of -49% to +49%; * platelet count change of -49% to +49%; * hemoglobin \< 11.0 g/dL or change \< 50% from baseline or change \< 2 g/dL; * neutrophils change of -49% to +49%.

    Time frame: Clinical response was assessed at Weeks 4, 8, 12, 16, and 24 for DCR assessment

  6. Overall Survival (OS)

    Overall survival is defined as the time from the date of the participant's first dose of any study drug to death from any cause. OS was calculated using Kaplan-Meier methods.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  7. Number of Eligible Participants Reaching Autologous or Allogeneic Transplantation

    Participants eligible for autologous or allogeneic transplantation were transplant-naïve participants who achieved CR.

    Time frame: From first dose of study drug to end of study; median time on study was 30.1 weeks.

  8. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are any event with onset after the first dose of study drug and no more than 30 days after the last dose of study drug. A serious AE was an event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity, or an important medical event requiring medical or surgical intervention to prevent a serious outcome. The Investigator rated the severity of each AE according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening and grade 5 = death. The Investigator assessed the relationship of the AE to the use of study drug.

    Time frame: From first dose of study drug up to 30 days after last dose; median time on treatment was 13.86 weeks (range 1.0 to 44.4 weeks)

08

Results

Posted Dec 19, 2022

Participant flow

In total, 16 adults with relapsed or refractory T-cell prolymphocytic leukemia (R/R T-PLL) were screened, and 14 participants were enrolled across 10 sites in 7 countries (Australia, France, Germany, Italy, Netherlands, United Kingdom, and United States).

Participant flow — Overall Study
MilestoneVenetoclax + Ibrutinib
Started14
Completed0
Not completed14
Withdrew: Withdrawal by subject1
Withdrew: Death9
Withdrew: Lost to follow-up1
Withdrew: Study terminated by sponsor1
Withdrew: Other2

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial remission (PR) as their best response per investigator assessment based on the T-PLL consensus criteria 2019. CR: All of the following response criteria must be met: Group A: * all lymph nodes \< 1 cm; * spleen \< 13 cm; * no constitutional symptoms; * circulating lymphocyte count \< 4 × 10\^9/L; * bone marrow T-PLL cells \< 5% of mononuclear cells; * no other specific site involvement Group B: * platelets ≥ 100 × 10\^9 /L; * hemoglobin ≥ 11.0 g/dL; * neutrophils ≥ 1.5 × 10\^9 /L. CRi: All of the CR response criteria in Group A met; at least 1 parameter in Group B not achieved, unrelated to T-PLL, but related to drug toxicity. PR: At least 2 of the parameters in Group A and 1 parameter in Group B need to improve if previously abnormal. If only 1 parameter of both Groups A and B is abnormal prior to therapy, only 1 parameter needs to improve.

Time frame:
Clinical response was assessed at Weeks 4, 8, 12, 16, and 24 for ORR assessment
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsVenetoclax + Ibrutinib
Overall Response Rate (ORR)7.1 (0.2 to 33.9)
SecondaryProgression-Free Survival (PFS)

Progression-free survival is defined as the time from the date of first dose of any study drug to the date of earliest disease progression or death. PFS was calculated using Kaplan-Meier methods. Response was assessed by the investigator based on the T-PLL consensus criteria 2019. Progressive disease (PD) is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in sum of long-axis diameters of up to 3 target lesions (SLD) from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsVenetoclax + Ibrutinib
Progression-Free Survival (PFS)2.7 (1.2 to 5.3)
SecondaryDuration of Response (DOR)

Duration of response is defined for participants who achieved a best overall response of CR, CRi, or PR as the time from the date of first response (CR, CRi, or PR) to the earliest date of disease progression or death. DOR was calculated using Kaplan-Meier methods. Response was assessed by the investigator based on the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.
Reported as:
Median · months
Duration of Response (DOR)
monthsVenetoclax + Ibrutinib
Duration of Response (DOR)4.6 (4.6 to 4.6)
SecondaryTime to Progression (TTP)

Time to progression is defined as the time from the date of the participant's first dose of any study drug to the date of earliest disease progression. TTP was calculated using Kaplan-Meier methods. Clinical response (laboratory and physical examination assessments) was assessed by the investigator according to the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.
Reported as:
Median · months
Time to Progression (TTP)
monthsVenetoclax + Ibrutinib
Time to Progression (TTP)2.7 (1.2 to 5.3)
SecondaryEvent-free Survival (EFS)

Event-free survival is defined as time from participant's first dose of any study drug to the date of earliest disease progression, death, or start of a new anti-T-PLL therapy. EFS was calculated using Kaplan-Meier methods. Clinical response (laboratory and physical examination assessments) was assessed by the investigator according to the T-PLL consensus criteria 2019. Progressive disease is defined as meeting at least one of the criteria of Group A or Group B below: Group A: * lymph nodes increase in \> 20% in SLD from nadir; * spleen increase ≥ 50% in vertical length beyond normal from baseline; * circulating lymphocyte count increase ≥ 50% from baseline; * appearance of a new lesion; Group B: * platelet count decrease of ≥ 50% from baseline due to T-PLL (not due to drug toxicity); * hemoglobin decrease of ≥ 2 g/dL from baseline due to T-PLL; * neutrophils decrease of ≥ 50% from baseline due to T-PLL.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.
Reported as:
Median · months
Event-free Survival (EFS)
monthsVenetoclax + Ibrutinib
Event-free Survival (EFS)2.6 (0.6 to 5.3)
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants who achieved CR, CRi, PR, or stable disease (SD) as best overall response per investigator assessment based on the T-PLL consensus criteria 2019. Stable disease is defined as meeting all of the following criteria for at least 3 months: * lymph nodes change of -29% to +20% in SLD; * spleen change of -49% to +49% beyond normal from baseline; * circulating lymphocyte count \> 30 × 10\^9 /L or change of -49% to +49%; * platelet count change of -49% to +49%; * hemoglobin \< 11.0 g/dL or change \< 50% from baseline or change \< 2 g/dL; * neutrophils change of -49% to +49%.

Time frame:
Clinical response was assessed at Weeks 4, 8, 12, 16, and 24 for DCR assessment
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsVenetoclax + Ibrutinib
Disease Control Rate (DCR)28.6 (8.4 to 58.1)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of the participant's first dose of any study drug to death from any cause. OS was calculated using Kaplan-Meier methods.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.
Reported as:
Median · months
Overall Survival (OS)
monthsVenetoclax + Ibrutinib
Overall Survival (OS)7.3 (1.6 to 10.9)
SecondaryNumber of Eligible Participants Reaching Autologous or Allogeneic Transplantation

Participants eligible for autologous or allogeneic transplantation were transplant-naïve participants who achieved CR.

Time frame:
From first dose of study drug to end of study; median time on study was 30.1 weeks.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs are any event with onset after the first dose of study drug and no more than 30 days after the last dose of study drug. A serious AE was an event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity, or an important medical event requiring medical or surgical intervention to prevent a serious outcome. The Investigator rated the severity of each AE according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening and grade 5 = death. The Investigator assessed the relationship of the AE to the use of study drug.

Time frame:
From first dose of study drug up to 30 days after last dose; median time on treatment was 13.86 weeks (range 1.0 to 44.4 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
ParticipantsVenetoclax + Ibrutinib
Any adverse event14
AE with NCI-CTCAE toxicity Grade 3, 4, or 511
Serious adverse event8
AE leading to venetoclax discontinuation, incl PD11
AE leading to venetoclax interruption9
AE leading to venetoclax reduction2
AE with reasonable possibility related to venetoclax10
AE leading to ibrutinib discontinuation, incl PD11
AE leading to ibrutinib interruption10
AE leading to ibrutinib reduction1
AE with reasonable possibility related to ibrutinib13
Serious AE with reasonable possibility related to venetoclax3
Serious AE with reasonable possibility related to ibrutinib4
AE leading to death5
All deaths10

Adverse events

Collected over All-cause mortality is reported from enrollment through the end of study; median time on study was 30.1 weeks. Adverse events are reported from first dose of study drug up to 30 days after last dose; median time on treatment was 13.86 weeks (range 1.0 to 44.4 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax + Ibrutinib10/14 (71.4%)8/14 (57.1%)14/14 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventVenetoclax + Ibrutinib
DISEASE PROGRESSIONGeneral disorders4/14
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/14
ANAEMIABlood and lymphatic system disorders1/14
NEUTROPENIABlood and lymphatic system disorders1/14
NAUSEAGastrointestinal disorders1/14
EUTHANASIAGeneral disorders1/14
ASPERGILLUS INFECTIONInfections and infestations1/14
INFECTIONInfections and infestations1/14
OROPHARYNGEAL CANDIDIASISInfections and infestations1/14
FACET JOINT SYNDROMEMusculoskeletal and connective tissue disorders1/14
Most frequent other events
Showing 10 of 91
Most frequent other events
EventVenetoclax + Ibrutinib
DIARRHOEAGastrointestinal disorders8/14
NAUSEAGastrointestinal disorders6/14
DISEASE PROGRESSIONGeneral disorders5/14
ANAEMIABlood and lymphatic system disorders3/14
FATIGUEGeneral disorders3/14
DIZZINESSNervous system disorders3/14
RASHSkin and subcutaneous tissue disorders3/14
CONSTIPATIONGastrointestinal disorders2/14
VOMITINGGastrointestinal disorders2/14
INFECTIONInfections and infestations2/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Venetoclax + Ibrutinib
Mean66.8 ± 9.74
Age, Customized
Age, Customized(Participants)Venetoclax + Ibrutinib
< 40 years0
40 - < 65 years5
≥ 65 years9
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax + Ibrutinib
Female8
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Venetoclax + Ibrutinib
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Venetoclax + Ibrutinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Disease Duration
Disease Duration(years)Venetoclax + Ibrutinib
Mean3.229 ± 3.2134
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Venetoclax + Ibrutinib
0 (Fully active)7
1 (Restricted activity but ambulatory and able to work)6
2 (Ambulatory but unable to work)1
09

Study locations

15 sites
  • Dana-Farber Cancer Institute /ID# 207728
    Boston, Massachusetts 02215, United States
  • Mayo Clinic - Rochester /ID# 207692
    Rochester, Minnesota 55905-0001, United States
  • University of Texas MD Anderson Cancer Center /ID# 207746
    Houston, Texas 77030, United States
  • Peter MacCallum Cancer Ctr /ID# 209554
    Melbourne, Victoria 3000, Australia
  • Medizinische Universitaet Wien /ID# 208497
    Vienna, Wien 1090, Austria
  • Helsinki University Hospital /ID# 208108
    Helsinki, Uusimaa 00290, Finland
  • HCL - Hôpital Lyon Sud /ID# 208731
    Pierre Benite CEDEX, Auvergne-Rhone-Alpes 69495, France
  • CHRU Lille - Hopital Claude Huriez /ID# 208726
    Lille, Hauts-de-France 59037, France
  • Hopital Pitie Salpetriere /ID# 208730
    Paris, 75013, France
  • University Hospital Cologne /ID# 208834
    Cologne, 50937, Germany
  • Azienda Sanitaria Universitaria Giuliano Isontina /ID# 211487
    Trieste, 34128, Italy
  • Maxima Medisch Centrum /ID# 207989
    Eindhoven, 5631 BM, Netherlands
  • Universitair Medisch Centrum Groningen /ID# 207990
    Groningen, 9713 GZ, Netherlands
  • Oxford University Hospitals NHS Foundation Trust /ID# 211264
    Oxford, Oxfordshire OX3 9DU, United Kingdom
  • The Royal Marsden NHS Foundation Trust /ID# 211263
    London, SW3 6JJ, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Nov 2021, 21 months.

Results were first posted in Dec 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 13, 2019
StartActual
Jan 14, 2020
Primary completionActual
Nov 4, 2021
CompletionActual
Nov 4, 2021
Results first posted
Dec 19, 2022
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03873493
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Jan 14, 2020
Primary completion
Nov 4, 2021
Completion
Nov 4, 2021
Results posted
Dec 19, 2022
Last update
Dec 19, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Ibrutinib

Start the discussion